Evidence map›Paper›PMID 36756130›Full record

ArticleFrontiers in immunology2023

SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses.

Dennis Christensen, Charlotta Polacek, Daniel J Sheward, Leo Hanke, Gerald McInerney, Ben Murrell, Katrine Top Hartmann, Henrik Elvang Jensen, Julie Zimmermann, Gregers Jungersen and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Dennis ChristensenCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
Charlotta PolacekVirus Research and Development Laboratory, Department of Microbial Diagnostic and Virology, Statens Serum Institut, Copenhagen, Denmark.
Daniel J ShewardDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Leo HankeDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Gerald McInerneyDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Ben MurrellDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Katrine Top HartmannDepartment of Veterinary and Animal Sciences, University of Copenhagen, Copenhagen, Denmark.
Henrik Elvang JensenDepartment of Veterinary and Animal Sciences, University of Copenhagen, Copenhagen, Denmark.
Julie ZimmermannCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
Gregers JungersenCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
Kristin Engelhart IlligenCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
Louise Krag IslingCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
Carlota Fernandez-AntunezCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
Santseharay RamirezCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
Jens BukhCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
Gabriel Kristian PedersenCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
Statens Serum Institut · DKUniversity of Copenhagen · DKKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 continues to pose a threat to human health as new variants emerge and thus a diverse vaccine pipeline is needed. We evaluated SARS-CoV-2 HexaPro spike protein formulated in Alhydrogel

Indexed as

COVID-19SARS-CoV-2Aluminum HydroxideAnimalsAntibodies, NeutralizingCricetinaeHumansMesocricetusVaccinationAluminum HydroxideAntibodies, Neutralizingaccelerated schedulealumneutralizing antibodiesSARS-CoV-2subunit vaccine

Identifiers

PMID36756130
PMCPMC9900178
OpenAlexW4317728328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.